Inactivating mutations in NPC1L1 and protection from coronary heart disease.
Stitziel NO
N Engl J Med. 2014 Nov 12;371(22):2072-82. doi: 10.1056/NEJMoa1405386
IL1R8 Deficiency Drives Autoimmunity-Associated Lymphoma Development.
Riva F
Cancer Immunol Res. 2019 Apr 24;7(6):874-885. doi: 10.1158/2326-6066.CIR-18-0698
Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity.
Mantovani A
Immunity. 50(4):778-795. doi: 10.1016/j.immuni.2019.03.012
Interleukin-1 in tumor progression, therapy, and prevention.
Garlanda C, Mantovani A
Cancer Cell. 2021 May 13;39(8):1023-1027. doi: 10.1016/j.ccell.2021.04.011
IL-1R8 silencing improves the anti-tumor function of freshly isolated human NK cells.
Landolina N
J Immunother Cancer. 10(3)doi: 10.1136/jitc-2021-003858
Immunotherapy for cardiovascular disease.
Martini E, Stirparo GG, Kallikourdis M
J Leukoc Biol. 2017 Dec 19;103(3):493-500. doi: 10.1002/JLB.5MR0717-306R
Immunometabolic Mechanisms of Heart Failure with Preserved Ejection Fraction.
Schiattarella GG
Nat Cardiovasc Res. 2022 Mar 14;1(3):211-222. doi: 10.1038/s44161-022-00032-w
Influence of the d3GH receptor polymorphism on the metabolic and biochemical phenotype of GH-deficient adults at baseline and during short- and long-term recombinant human GH replacement therapy.
Giavoli C
Eur J Endocrinol. 2010 Jun 30;163(3):361-8. doi: 10.1530/EJE-10-0317
Identification of human somatostatin receptor 2 domains involved in internalization and signaling in QGP-1 pancreatic neuroendocrine tumor cell line.
Cambiaghi V
Endocrine. 2016 Jul 12;56(1):146-157. doi: 10.1007/s12020-016-1026-2
IRF4 instructs effector Treg differentiation and immune suppression in human cancer.
Alvisi G
J Clin Invest. 130(6):3137-3150. doi: 10.1172/JCI130426